{"filing":{"accession_number":"0001213900-26-063125","cik":"0001821586","ticker":"MLTX","company_name":"MoonLake Immunotherapeutics","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"ea0292693-8k_moonlake.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390026063125/ea0292693-8k_moonlake.htm"},"events":[{"id":7848,"run_id":6885,"accession_number":"0001213900-26-063125","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"MoonLake entered into a Master Commercial Supply Agreement with Vetter Pharma on May 22, 2026, establishing a binding manufacturing and supply relationship for the Company's product candidates, including sonelokimab. The agreement includes capacity reservations, pricing terms, and termination provisions that create material commercial obligations. While this is a supply/manufacturing agreement rather than a traditional M\u0026A transaction, it represents a material definitive agreement that would affect investor assessment of the Company's manufacturing strategy and operational commitments.","company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3219,"accession_number":"0001213900-26-063125","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"MoonLake entered into a Master Commercial Supply Agreement with Vetter Pharma on May 22, 2026, establishing a binding manufacturing and supply relationship for the Company's product candidates, including sonelokimab. The agreement includes capacity reservations, pricing terms, and termination provisions that create material commercial obligations. While this is a supply/manufacturing agreement rather than a traditional M\u0026A transaction, it represents a material definitive agreement that would affect investor assessment of the Company's manufacturing strategy and operational commitments.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:44:19.969172+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3219,"accession_number":"0001213900-26-063125","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"MoonLake entered into a Master Commercial Supply Agreement with Vetter Pharma on May 22, 2026, establishing a binding manufacturing and supply relationship for the Company's product candidates, including sonelokimab. The agreement includes capacity reservations, pricing terms, and termination provisions that create material commercial obligations. While this is a supply/manufacturing agreement rather than a traditional M\u0026A transaction, it represents a material definitive agreement that would affect investor assessment of the Company's manufacturing strategy and operational commitments.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:44:19.969172+00:00","company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","filing_date":"2026-06-01"}]}